RYTM:NASDAQ, Rhythm Pharmaceuticals, Inc.
RYTM stock overview
Rhythm Pharmaceuticals, Inc. (RYTM:NASDAQ) closed at $107.48 on November 16, 2026,
down 6.56% on the day.
The stock trades 12.0% below its 52-week high of $122.20
and 44.3% above its 52-week low of $74.50.
Over the past year, it gained 6.7%.
Rhythm Pharmaceuticals, Inc. is part of the Health Care sector (Major Pharmaceuticals).
Key figures
- Price
- $107.48
- Day change
- -6.56%
- Volume
- 947,267
- Average volume
- 1,008,140
- Market cap
- 7B+
- 52-week range
- $74.50 – $122.20
- 50-day average
- $96.88
- 200-day average
- $97.24
Price action over the past year
In 252 trading sessions since November 14, 2025, RYTM closed higher on 127 days (50%).
Its best day was November 4, 2026 (+28.04%) and its worst was November 3, 2026 (-7.49%).
The stock moved 10% or more in a single session 3 times.
It opened at least 5% above the previous day's high 3 times.
Recent signals
RYTM news
-
Nov 5, 2026:
European Stocks Close Mostly Lower in Thursday Trading as Investors Parse Earnings Reports, US Elections, Rising Oil Prices
-
Nov 4, 2026:
RYTM Stock Clocks Best Day In Nearly 16 Months On AstraZeneca $10B Bid Report
-
Nov 4, 2026:
Rhythm Pharmaceuticals stock surges 28% on AstraZeneca bid report
-
Nov 4, 2026:
AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals
-
Nov 4, 2026:
Could Rhythm Pharmaceuticals (RYTM) Be Too Pricey After Recent Funding?
-
Nov 4, 2026:
Rhythm Pharmaceuticals Stock In Focus After Earnings Beat And $750 Million Financing
-
Nov 4, 2026:
Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome
-
Nov 4, 2026:
Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome
About Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders.
Similar stocks
Find more stocks like RYTM with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.